T he profound effects of bariatric surgery on glycemic control are well established in many studies, including several randomized trials that compared surgery versus intensive medical and lifestyle treatment of type 2 diabetes mellitus (T2DM) (1-7). Remission of T2DM is common after bariatric surgery, and Roux-en-Y gastric bypass (RYGB) outperforms sleeve gastrectomy (SG) in most reports (4, 8, 9) .
More important than improvements in glycemic control is whether these glycemic changes reduce the incidence of major complications, such as microvascular events. In the United States, T2DM is the primary cause of nephropathy, end-stage renal disease, adult blindness, and neuropathy, which together lead to significant downstream costs and decreased quality of life (10 -12). Thus, a major goal of diabetes treatment is to mitigate the risk for these long-term sequelae (13).
We have previously shown that in patients with T2DM who have bariatric surgery, risk for incident microvascular disease is reduced for every year of remission from T2DM-even if patients eventually relapse back to T2DM (indicating a legacy effect) (14). However, a detailed 2016 review of long-term microvascular outcomes of diabetes concluded that data were inadequate to support a superior effect of bariatric surgery compared with medical therapy (15).
Two recently published studies help inform this question (4, 16). The STAMPEDE (Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently) trial (4) randomly assigned 150 patients with obesity and T2DM to have RYGB, SG, or an intensive medical and lifestyle intervention. After 5 years, urinary albumincreatinine ratios had decreased in the SG group only. Retinopathy did not change in any group, and neuropathy was not examined. STAMPEDE was limited by a relatively small sample size, which made it underpowered for rare outcomes.
The prospective SOS (Swedish Obesity Subjects) matched cohort study (16) at baseline. The SOS study was limited by the small number of RYGB procedures and lack of SG procedures, which are now the 2 most common bariatric procedures worldwide (17) .
To address these gaps in the literature, we did a matched cohort study to determine whether bariatric surgery was associated with lower incidence of microvascular disease than usual care for severe obesity and T2DM. We hypothesized that patients having bariatric surgery would have lower risk for any incident microvascular disease (composite of the first occurrence of retinopathy, neuropathy, or nephropathy). We further hypothesized that patients having bariatric surgery would have lower risk for incident retinopathy, nephropathy, and neuropathy than nonsurgical patients.
METHODS

Settings
We did a retrospective observational cohort study of adults with T2DM who had bariatric surgery between 2005 and 2011 while enrolled in 1 of 4 integrated health care systems from the Health Care Systems Research Network: Kaiser Permanente (KP) Washington in Washington state, HealthPartners in Minnesota, KP Northern California, and KP Southern California. All study procedures were reviewed and approved by the institutional review board at each site, and we were permitted to do the research without explicit consent from participants.
Data Sources
At each study site, staff used standardized electronic medical records, insurance claims, and other data systems (18) to extract enrollee data, including enrollment and insurance coverage; demographics; blood pressure; height; weight; laboratory values; medications dispensed; deaths; outpatient, inpatient, and emergency department use; and inpatient and outpatient diagnosis and procedure codes.
Surgical Participants
The (HbA 1c ) level of at least 6.5% or fasting plasma glucose level of at least 6.99 mmol/L (126 mg/dL) at the most recent measurement within 2 years before surgery, or a current prescription for any diabetes medication.
After selecting the population, we applied the following exclusion criteria based on information in the 2 years before surgery: less than 1 full year of continuous enrollment; history of gastrointestinal surgery for cancer; pregnancy in the year before surgery; gestational diabetes as the sole diabetes diagnosis; metformin as the sole indicator of possible T2DM (that is, no other T2DM medications, laboratory values, or diagnoses); preexisting neuropathy, retinopathy, or nephropathy (defined in Outcome and Censoring Definitions); and maximum preoperative BMI less than 35 kg/m 2 . This left 4972 patients. We further excluded 850 patients who were missing values for BMI, HbA 1c level, or serum creatinine concentration in the 2 years before surgery. Surgical patients who were missing these values differed from those who had complete data (Appendix Table 1 , available at Annals.org). Specifically, they were Figure 1 ).
Matched Nonsurgical Participants
For each surgical patient, we identified up to 3 matched nonsurgical control participants via a 2-step process. First, among all patients with diabetes and at least 1 BMI measurement of 35 kg/m 2 or greater who did not have bariatric surgery during the study (n = 320 345), we identified a pool of potential control participants who were enrolled at the time of the surgery; satisfied the study inclusion criteria; and matched the surgical patient on the basis of study site, sex, age (±10 years), BMI (±5 kg/m 2 ), HbA 1c level (±1.5 percentage points), and insulin use. Second, for each control participant in the pool, we calculated Mahalanobis distance from the surgical patient on the basis of age, BMI, HbA 1c level, diabetes duration, and total days of health care use in the 7 to 24 months before the date of surgery (21) . Finally, up to 3 control participants were selected on the basis of the shortest Mahalanobis distance. Throughout, nonsurgical patients could be used as a control for only 1 surgical patient (matching without replacement). The Appendix (available at Annals .org) gives additional details on the process we used to establish the matched cohort.
Outcome and Censoring Definitions
The primary outcome measure was time to incident microvascular disease (composite of the first occurrence of retinopathy, neuropathy, or nephropathy). Retinopathy was defined by the first appearance of either ICD-9 code 362.0x (diabetic retinopathy) or both a retinal surgical procedure code or other retinopathic code (Appendix Table 2 , available at Annals.org) and ICD-9 code 250.5x (diabetes with ophthalmic manifestations). Neuropathy was identified on the basis of the first occurrence of ICD-9 code 250.6 (diabetes with neurologic manifestations) or 357.2 (polyneuropathy in diabetes). Finally, nephropathy was defined by at least 2 measures of estimated glomerular filtration rate less than 60 mL/min/1.73 m 2 separated by at least 90 days without any intervening values of 60 mL/min/1.73 m 2 or greater. We approximated estimated glomerular filtration rate using serum creatinine values and the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation (22) . We chose not to use urine protein measures to define incident nephropathy because nearly 25% of our cohort had no baseline measurements of urine protein. Patients were censored at first incidence of cancer (excluding nonmelanoma skin cancer), disenrollment, death, study end (31 September 2015), or a period of 13 months with no measurement of weight or blood pressure (Appendix Table 3 , available at Annals.org). In secondary analyses, we considered each of the 3 component microvascular outcomes separately. 
Statistical Analysis
Cox hazards regression models were used to investigate the association between bariatric surgery (versus usual care in nonsurgical control participants) and incident microvascular disease. Patients were followed from the index date (date of surgery or, for nonsurgical patients, date of surgery for their matched case patient) until the first occurrence of incident microvascular disease or a censoring event. On the basis of preliminary analyses, the proportional hazards assumption was assessed not to hold for bariatric surgery versus usual care (P < 0.001 for an interaction with log time in the Cox model). We therefore fitted a flexible time-varying HR association as a function of time since surgery, using restricted cubic splines with knots at the 5th, 35th, 65th, and 95th percentiles of the observed follow-up time scale (23) .
Potential confounders of the association between bariatric surgery and microvascular disease were identified a priori. Our 2-part matching strategy was designed to ensure balance between surgical and nonsurgical patients for many factors (see Matched Nonsurgical Participants), and we achieved an exact balance for select matching covariates (such as sex and insulin use). We also fitted the Cox models for the primary and secondary outcomes, adjusting for the following covariates: age, race/ ethnicity (Hispanic, non-Hispanic white, non-Hispanic black, or non-Hispanic other), year of surgery, BMI, smoking status (current, former, or never), duration of observed diabetes before surgery (defined as first observed diagnosis, laboratory value, or prescription indicating T2DM), insulin use, oral diabetes medication use, uncontrolled blood pressure (defined as either systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg at 2 consecutive measures on different days), use of angiotensin-converting enzyme inhibitor or angiotensinreceptor blocker medications, use of any other antihypertensive medication, insurance type (commercial, Medicare, Medicaid, or other), triglyceride level of 2.82 mmol/L (250 mg/dL) or greater, use of cholesterol-lowering medication (statin or other), use of aspirin or another platelet inhibitor, and history of a cardiac or cerebrovascular event before surgery (defined on the basis of ICD-9 codes). Because of potential variation in care between health systems, we adjusted for study site (HealthPartners, KP Southern California, KP Northern California, and KP Washington) via stratification of the baseline hazard function. Of note, by including variables used in matching or Mahalanobis distance calculation in the Cox models, our analyses provide 2 (parallel) adjustments for potential confounding effects.
Some data were missing at baseline for race/ ethnicity, smoking status, blood pressure, and triglyceride levels. We did multiple imputation via chained equations, using unordered categorical variables and multinomial logistic regression for imputation of race/ ethnicity and smoking status and logistic regression for elevated blood pressure and triglyceride levels (24) . We generated 10 imputed data sets and combined the results using Rubin rules. The Appendix provides more details.
We did 3 sensitivity analyses to examine the effect of not adjusting for potential confounders excluded from the matching process (vs. adjusting for those confounders in our main analysis), the effect of using 1:1 and 10:1 matching, and the effect of assessing robustness of the 5-year results to unmeasured confounding using the E-value method of VanderWeele and Ding (25) . Throughout, we used SAS, version 9.4 (SAS Institute), for data manipulation; Stata, version 15.1 (StataCorp), for multiple imputation and analysis; and R for visualization.
Role of the Funding Source
The National Institute of Diabetes and Digestive and Kidney Diseases had no role in the design or conduct of the study or reporting of the results.
RESULTS
Participants
The final analytic sample comprised 4024 surgical patients and 11 059 nonsurgical matches ( Table 1) . Median follow-up was 4.3 years in both groups, and retention rates at 1, 3, and 5 years were similar for nonsurgical (90%, 67%, and 56%) and surgical (90%, 69%, and , 38% had had T2DM for 5 years or more before baseline, and the mean HbA 1c level was 7.1%. More nonsurgical patients had been current smokers in the 2 years before surgery (13.7% vs. 9.7%), and more nonsurgical patients had been using medications to control hypertension.
Effect of Bariatric Surgery Versus Usual Care on Risk for Incident Microvascular Disease
Figure 2 (A to D) and Table 2 show estimates of the cumulative probability of incident microvascular disease over time after bariatric surgery and nonsurgical care (for matched control participants), as well as the cumulative probability of each of the indicators of microvascular disease (nephropathy, neuropathy, and retinopathy). Rates of incident microvascular disease at 1, 3, 5, and 7 years were 6.0%, 11.8%, 16.9%, and 22.5%, respectively, after bariatric surgery and 11.2%, 24.3%, 34.7%, and 44.2% after usual care. The difference was primarily driven by the incidence of neuropathy, which was lower for surgical than nonsurgical participants. Rates of retinopathy were also lower in surgical patients. Cumulative incidence rates of nephropathy were similar among surgical and nonsurgical patients (2.7% and 2.8%) in the first year after surgery; however, rates of nephropathy were lower among surgical patients at all time points after 1 year. Figure 2 (E to H) shows the change in adjusted HR over time for each outcome. The HR for all microvascular events decreased after the index date (favoring surgery) and remained relatively stable after 1 year. Bariatric surgery was associated with a stable decrease in risk for neuropathy over time. Risk for nephropathy was initially higher among surgical patients but decreased rapidly and remained lower among surgical patients in years 1 through 7. The HR for retinopathy followed a trajectory similar to that of the composite index of all microvascular events, aside from a slight strengthening of the association starting 4 years after surgery. 
Sensitivity Analyses
Appendix Figures 1 and 2 (available at Annals.org) provide results of the sensitivity analyses. A matched, unadjusted analysis of our primary outcome was not significantly different from the fully adjusted model (Appendix Figure 1) . Our primary outcome results using 3:1 matching were qualitatively similar to those using 1:1 and 10:1 matching (Appendix Figure 2) . For the 5-year results reported in Table 3 , the E-values for the point estimate and upper confidence bound for incident microvascular disease were 3.09 and 2.70, respectively; the corresponding E-values for incident retinopathy were 3.04 and 2.08. We also found no differences in the frequency of microvascular disease surveillance across surgical and nonsurgical groups over 5 years of follow-up (Appendix Table 5 , available at Annals.org).
DISCUSSION
Prior studies have shown that most patients who have bariatric procedures experience a remission of their T2DM (20, 26) . However, less is known about whether bariatric surgery reduces risk for incident microvascular disease (15). In the current study, bariatric surgery was associated with half the incidence of microvascular disease at 5 years compared with usual medical care. A lower rate of neuropathy primarily drove this finding, but we also saw lower incidence of nephropathy and retinopathy through 5 years of follow-up.
Only 3 other studies of microvascular outcomes after bariatric surgery have included a nonsurgical popu- ORIGINAL RESEARCH Microvascular Outcomes After Bariatric Surgery lation as a comparator. These are the STAMPEDE randomized trial (4), which reported changes in microalbuminuria and retinopathy; the prospective SOS cohort study (16, 27, 28) , which reported neuropathy, nephropathy, and retinopathy incidence (using ICD-9, Clinical Modification, codes; ICD, 10th Revision, codes; nationwide registries; and albuminuria measures); and a retrospective cohort study by Johnson and colleagues (29) that included 2580 surgical patients and 13 371 matched control participants and reported incident endstage microvascular events. We place our findings in the context of these and other relevant studies. Among types of microvascular disease after bariatric surgery, renal outcomes have been studied most frequently. Despite varying definitions of renal outcomes, prior studies suggest that the outcomes of bariatric surgery are favorable for patients with and without renal disease at baseline (28, 30 -36) . In our study, incidence of nephropathy was 59% lower at 5 years among patients who had bariatric surgery. Recently published data from the STAMPEDE trial's 5-year follow-up (4) showed that urinary albumin-creatinine ratios were significantly better in the SG group than the medical therapy group (P < 0.001), but creatinine-based measures of renal function did not differ. Johnson and colleagues (29) reported a significant reduction in end-stage renal disease in patients who had bariatric surgery compared with matched nonsurgical patients. In the most recent study of microvascular outcomes, surgical patients with chronic kidney disease stage 3 or higher had significant improvements in estimated glomerular filtration rate compared with matched control participants, and patients having RYGB saw the greatest improvements (vs. those having SG) (35) .
The hazard of neuropathy at 5 years (defined by ICD-9, Clinical Modification, codes) was 63% lower at 5 years in our surgical cohort than in the usual care group. Few population-based studies have reported neuropathy independent of other microvascular outcomes (27, 29) . STAMPEDE (4) found a 50% reduction in neuropathy on a patient-reported questionnaire. Miras and associates (37) did not find any improvement in peripheral nerve conduction at 12 to 18 months in a small (n = 70) prospective case-control study.
We also report a 45% lower hazard of incident diabetic retinopathy at 5 years (defined using diagnosis and procedure codes) in surgical versus nonsurgical patients. Strict glycemic control is an important factor in preventing progression of diabetic retinopathy (38 -40), and bariatric surgery is superior to medical treatment in achieving T2DM remission (1-7). Despite this, the effects of bariatric surgery on diabetic retinopathy have been mixed: Some studies showed improvement (41), whereas others reported progression (42) (43) (44) (45) . Johnson and colleagues (29) showed fewer cases of blindness or retinal surgery in the surgical group than the nonsurgical group. Five-year data from the STAMPEDE study showed no evidence of benefit of RYGB or SG (vs. intensive lifestyle and medical treatment) on retinopathy rates (4). The SOS study did not examine retinopathy independent of other microvascular outcomes (27) .
Factors are at play that may mitigate the potential benefit of improved glycemic control with bariatric surgery on the incidence of retinopathy. These include an overly rapid decrease in HbA 1c level (which was associated with early worsening of diabetic retinopathy in the DCCT [Diabetes Control and Complications Trial]) (46), hypoglycemia after bariatric surgery (47), discontinuation of fenofibrate and angiotensin-receptor blockers after bariatric surgery (these medications can reduce risk for retinopathy but may be discontinued after bariatric surgery in patients whose diabetes is in remission) (48, 49), pregnancy (weight loss can reduce infertility, increasing the chance of pregnancy, which may worsen retinopathy) (50), and vitamin deficiencies (particularly vitamins A, D, and B12; copper; and folate) (51-55). Despite these potential negative effects of bariatric surgery on retinal outcomes, we observed a strong association with lower retinopathy risk over time.
Several factors limit the interpretation of our results. First, the observational study design precludes causal inference, and residual unmeasured confounding by indication might be present. Second, we adjusted for health system in our models, but we could not adjust at the level of clinic or provider, which could have caused unmeasured confounding due to differences in care quality. However, our sensitivity analyses indicate that each 5-year outcome (Table 3) had an E-value greater than 2 for the upper bound of the CI; this suggests, for example, that the results could be explained by an unmeasured confounder that was associated with both receipt of bariatric surgery and risk for microvascular disease by a risk ratio of 2.7, beyond the measured confounders. For our study, we believe that this degree of confounding remains unmeasured is implausible and, as such, do not believe that our conclusions would change. Third, data used to define incident microvascular disease (retinopathy, nephropathy, and neuropathy) were collected as part of routine clinical care across 4 large, integrated health care systems, so that missing data (eye examinations, blood tests, and neuropathy assessments) may have resulted in misclassification of microvascular complication status for some patients. Fourth, neuropathy may be misclassified because it was not identified using an objective end point and its symptoms, such as paresthesias, are common.
Not all patients will be interested in bariatric surgery to treat their T2DM, but providers should engage all patients with T2DM and a BMI of 35 kg/m 2 or higher in a shared decision-making conversation about the benefits and risks of bariatric procedures (56). Our results add to a growing body of evidence suggesting that bariatric surgery not only improves glucose, blood pressure, and lipid control but is likely to reduce macrovascular and microvascular complications, as well as improve survival, in patients with severe obesity and T2DM (57). The findings from this study should help patients and providers to better understand the potential tradeoffs of bariatric surgery as treatment of T2DM and help them to make more informed decisions about care. 
org). Data set:
Our data access committee will review any requests for access to data and make a determination. Please contact Dr. Arterburn for details on making a request (e-mail, arterburn.d@ghc .org). When matching is done on the basis of the propensity score, it is critical to check post hoc the balance in confounder distributions between the treatment groups. Given our use of a combination of exact and Mahalanobis distance-based matching, however, we checked balance by constructing and reporting Table 1 (that is, presenting baseline characteristics by exposure status). From this, we believe that we achieved reasonable balance. Nevertheless, we took a conservative approach to the analysis and explicitly adjusted for all potential confounders, including those in the matching process. Thus, our control of confounding does not rely exclusively on the success of the balancing.
Statistical Analysis
Given that the primary outcome is a time-to-event outcome, we investigated the association between surgery or nonsurgery and incident microvascular disease via a Cox model. Patients were followed from the index date (date of bariatric surgery or, for nonsurgical patients, date of surgery for the patient to whom they had been matched) until the first occurrence of either incident microvascular disease or a censoring event. After preliminary modeling, the proportional hazards assumption was assessed not to hold for bariatric surgery versus usual care (P < 0.001 for an interaction with log time in the Cox model). We therefore fitted a flexible time-varying HR association, as a function of time since surgery, using restricted cubic splines with knots at the 5th, 35th, 65th, and 95th percentiles of the observed follow-up time scale. Adjusted models were fitted that included age, race/ethnicity (Hispanic, non-Hispanic white, non-Hispanic black, or non-Hispanic other), year of surgery, BMI, smoking status (current, former, or never), duration of observed diabetes before surgery (defined as first observed diagnosis, laboratory value, or prescription indicating T2DM), insulin use, oral diabetes medication use, uncontrolled blood pressure (defined as either systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg at 2 consecutive measures on different days), use of angiotensinconverting enzyme inhibitor or angiotensin-receptor blocker medications, use of any other antihypertensive medication, insurance type (commercial, Medicare, Medicaid, or other), triglyceride level of 2.82 mmol/L (250 mg/dL) or greater, use of cholesterol-lowering medication (statin or other), use of aspirin or another platelet inhibitor, and history of a cardiac or cerebrovascular event before surgery (defined on the basis of ICD-9 codes). Because of potential variation in care between health systems, we adjusted for study site (HealthPartners, KP Southern California, KP Northern California, and KP Washington) via stratification of the baseline hazard function. Missing data were imputed using chained equations, as detailed elsewhere in the Appendix.
Overall Approach to Confounding
Collectively, the matched cohort design and the analytic approach just described provide 2 (parallel) approaches to controlling confounding bias. Sjö lander and Greenland (58) provide a detailed justification for including the covariates used in the matching process in the Cox regression models. In this sense, the extent to which confounding bias has been controlled does not rely solely on the extent to which the matching process has created perfect balance between surgical and nonsurgical patients.
Cumulative Incidence Plots
Figure 2 presents a series of plots that compare the cumulative incidence among bariatric case patients and noncase patients (for various outcome definitions). These figures are not "unadjusted" (as might typically be the case in Kaplan-Meier estimates of incidence) because they were calculated on the basis of the matched cohort. Moreover, because the matched adjusted and matched unadjusted Cox models yield nearly identical results, we believe that the cumulative incidence plots are a very reasonable approximation of the underlying rates in the 2 groups.
SE Estimation
Because all covariates used to construct the matched cohort were included in the model, no further statistical adjustment for the design was necessary to obtain valid estimates. Beyond study site (which was adjusted for via stratification of the baseline hazard function), we did not adjust for clinical center within site, mostly because it is unclear how to "assign" a clinical center for a nonexposed person at the time of surgery. This, we believe, may be an inherent limitation of the matched cohort design as applied in our setting. However, we do not believe that adjustment for correlation due to clinical center would change our conclusions. The SE that underpins the 95% CI for the composite index measure (Table 3) is at most 0.06 across each of the years presented. In order for the 95% CI at year 1 for an HR of 0.38 to cover 1.0, for example, the SE would have to increase to approximately 0.32 (a >6-fold increase). In our experience, although adjusting for correlation can affect SEs, such a large effect is implausible.
Missing Data
Missing data manifested at 2 points in the study. First, 850 of the 4972 bariatric case patients (15%) who satisfied our inclusion criteria were missing values for BMI, HbA 1c level, or serum creatinine concentration in the 2 years before surgery. Second, in the final matched cohort, patients may have been missing select baseline covariates, specifically race/ethnicity, smoking status, elevated blood pressure, or elevated triglyceride levels.
Appendix Table 1 compares the characteristics of the 15% of surgical patients who were missing values for BMI, HbA 1c level, or serum creatinine concentration versus those who had complete preoperative data. These data show that surgical patients with missing data were similar in most characteristics. Those that did differ suggest that persons who were missing data were either new to our health care systems (that is, had not been receiving care long enough to have all of these baseline data captured in our systems) or had the procedure with a surgeon who was not in our integrated network (we are less likely to capture complete data, such as laboratory values and vital signs, on patients who receive care from surgeons outside our health systems because we receive only insurance claims for those patients). For example, patients missing data were more often from HealthPartners (35% missing vs. 4% nonmissing); were more often nonHispanic white (57% missing vs. 46% nonmissing); more often had their procedure in the first year of our study, 2005 (26% missing vs. 5% nonmissing); more often had a shorter duration of observed diabetes (72% missing vs. 61% nonmissing); more often had missing blood pressure and triglyceride measures (40% missing vs. 0.5% nonmissing); and more often had missing information on smoking status (72% missing vs. 6% nonmissing).
Missing data were encountered at baseline for race/ethnicity, self-reported smoking status, blood pressure, and triglyceride levels. Table 1 shows the amount of missing data for each variable, stratified by surgical versus control status. To address the issue of missing data, we performed multiple imputation via chained equations using Stata's built-in mi suite (24) . Race/ethnicity and smoking status were imputed using multinomial logistic regression, whereas uncontrolled blood pressure and high triglyceride levels were imputed via logistic regression. We detected no issues with perfect prediction or nonconvergence of models. The imputation used all variables involved in the 4 analytic models, including the outcome variables of timeto-event and event status. We used M = 10 imputations, with 100 iterations between saved data sets to prevent autocorrelation between imputations. Stata's "mi estimate" prefix was used to automatically combine the results of the Cox regressions using Rubin rules.
Software Used
Throughout, we used SAS, version 9.4 (SAS Institute), for data manipulation; Stata, version 15.1 (StataCorp) (59), for multiple imputation and analysis; and R, version 3.4.2 (60), for visualization. 
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